key: cord-0705224-67kyy8pq
authors: Eyal, Nir; Caplan, Arthur; Plotkin, Stanley
title: COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies
date: 2021-04-27
journal: Human vaccines & immunotherapeutics
DOI: 10.1080/21645515.2021.1917240
sha: c66214d36c9f1555dc64bbfd0631a56b2b527d34
doc_id: 705224
cord_uid: 67kyy8pq

nan

SARS-CoV-2's B.1.351 ("South African") variant "is markedly more resistant to neutralization by convalescent plasma (9.4 fold) and vaccinee sera (10.3-12.4 fold)," 1,2 raising the specter that that variant could resist the leading authorized spike-based vaccines. 2 Indeed, in earlier lab exams, Moderna's vaccine showed "A six-fold reduction in neutralizing titers . . . with the B.1.351 variant relative to prior variants." 3 Pfizer-BioNTech's "neutralization of the B.1.351-spike virus was weaker by approximately two thirds." 4 When tested in human volunteers, AstraZeneca's vaccine provided only 10% protection from mild to moderate disease caused by that variant, and its distribution in South Africa was suspended. 5 Janssen's vaccine also did less well in South Africa than elsewhere, presumably due to lower neutralization of infecting viruses. 6 It is of great urgency to test in human populations whether the leading authorized vaccines, their boosters in development, 7 and other vaccines in development strongly protect against SARS-CoV-2 viral variants. But now that authorized vaccines are being rolled out, and others may soon get emergency authorization, new placebo-controlled phase 3 field trials in nations with wide access to vaccines would have to exclude thousands of study participants from protective vaccines. That would pose substantial risk both to them and to their many contacts around study sitesa formidable ethical and public health challenge. 8 Noninferiority trials would either require an unacceptably high number of participants and last too long or compromise accepted statistical standards. Trials in countries without vaccine access would be ethically contentious and, even if possible, 9,10 take too long, and cost too much to be done for every variant and booster.

In this new landscape of vaccines gradually becoming available for all adults in rich nations, the quickest and perhaps only viable way to test vaccines for their efficacy against new variants (as well as to test new dosing regimens, discern the correlates and duration of vaccine protection, and rigorously assess vaccine impact on infection and infectiousness) is to conduct human challenge trials. In such trials, 1:100-1:1000 the participants of field trials, all selected to be young and healthy with extremely low risk of severe outcomes upon COVID infection, 11 are intentionally exposed to the relevant viral variant, typically by the nasopharyngeal administration of small doses. This is done only after a thorough process to verify their autonomous consent. Trialists then test the relevant vaccine regimen for protection against infection, with suitable controls. To protect wider communities, participants remain in isolation while potentially infectious.

Dose escalation for a human challenge trial of an old SARS-CoV-2 variant has begun in the UK. 12, 13 But the advent of new variants and the prospect of further mutations 1 make it urgent to conduct multiple human challenge trials -for multiple variants.

The UK and other governments should now start growing cultures for multiple variants -typically a 3-4 months-long process. The fact that companies "are already working on developing boosters and new shots specifically designed to address the mutant strains" 12 in no way "reduces the need for human challenge trials," 12 to reliably test such boosters and new shots in human subjects. While some of the emerging variants (not necessarily B.1.351) are more virulent than old ones, 14 risks in SARS-CoV-2 challenge trials for properly selected participants are so much lower 11 than commonly assumed that the added risk to participants would be well-justified even for these variants by the public health urgency -which that virulence similarly increases. And even if human challenge studies for some emerging variants remain too contentious right now, no human participants would be placed at risk by governments' growing culture to keep options open several months down the road. The UK government had approved the initial SARS-CoV-2 human challenge trials only after months of discussion and notwithstanding initial hesitation.

Human challenge trials are vital tools for rapidly achieving the requisite answers on alarming new viral variants. Now is the time to lay the groundwork for these crucial investigations.

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa

Neutralizing activity of BNT162b2-elicited serum -preliminary report

WHO backs use of Oxford/AstraZeneca Covid vaccine for adults of all ages

Fact sheet for healthcare providers administering vaccine-Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent Coronavirus disease 2019 (COVID-19); 2021

Moderna designs updated Covid-19 vaccine to combat South Africa coronavirus variant

Vaccine trial ethics once we have efficacious vaccines

Avoiding exploitation in multinational covid-19 vaccine trials

How to test SARS-CoV-2 vaccines ethically even after one is available

Exploring risks of human challenge trials for COVID-19

It's not clear that we actually need human challenge trials for COVID-19, but the U.K. is moving ahead with them anyway

Britain first to infect healthy volunteers with coronavirus for study

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study